Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

PEP-Therapy teams with CleveXel for peptide development
08-15-2015
SHARING OPTIONS:

PARIS & MAISONS-ALFORT, France—Biotechnology company PEP-Therapy and CleveXel Pharma have begun co-developing a peptide as a targeted therapy for the treatment of cancers with high medical need. PEP-Therapy and CleveXel Pharma will take the product through to clinical proof of concept, with the regulatory preclinical phase scheduled for the end of this year and clinical trials expected to begin by the end of 2016. PEP-Therapy will also continue developing companion biomarkers to accompany the product.
 
“For CleveXel Pharma, this partnership paves the way for real innovation in oncology. CleveXel Pharma’s know-how and expertise in development add value to this project. We have also been attracted by the involvement of biological and clinical researchers from Inserm, Pierre & Marie Curie University and Institut Curie,” Christian Bloy, CEO of CleveXel Pharma, noted in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.